The research collaboration will focus on novel therapies for AML, CML, ALL, myeloproliferative neoplasms, and myelofibrosis.
SAN DIEGO – These children face high rates of disease, and new research is shedding light on the reasons why.
Chemotherapy for solid tumors is associated with an increased risk of therapy-related myelodysplastic syndromes or acute myeloid leukemia (tMDS/...
From the Journals
Most tMDS/AML cases expected to occur within the next 5 years will be attributable to chemotherapy, the researchers reported.
SAN DIEGO – QuANTUM-R is the first randomized trial to show a survival benefit over salvage chemotherapy in patients with FLT3-ITD mutated AML.
SAN DIEGO – Too many patients die because numbers aren’t aggregated or shared, Dr. Ned Sharpless said at the ASH meeting.
SAN DIEGO—An algorithm has proven effective for identifying differentiation syndrome (DS) in patients taking ivosidenib or enasidenib, according...
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
SAN DIEGO – Dr. Keith W. Pratz reviewed results from a phase 1 study of gilteritinib and next steps in newly diagnosed patients.